Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jun 20, 2024

Later deadlines: Jul 19, 2024, Oct 21, 2024, Nov 21, 2024, Feb 21, 2025, Mar 21, 2025, Jun 23, 2025, Jul 23, 2025, Oct 20, 2025, Nov 20, 2025, Feb 20, 2026, Mar 20, 2026, Jun 22, 2026, Jul 22, 2026, Oct 19, 2026, Nov 19, 2026

Grant amount: Unspecified amount

Fields of work: Dementia & Alzheimer’s Disease

Applicant type: Nonprofit, Government Entity, Indigenous Group, For-Profit Business

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world


NOTE: There is currently one deadline for Letters of Intent; January 19, 2024. Applicants with questions about future deadlines are advised to contact a program officer.

The following full proposal deadlines apply to standard grant applications (due by 5:00 pm  local time of applicant organization):

  • February 21, 2024
  • June 20, 2024
  • October 21, 2024
  • February 21, 2025
  • June 23 , 2025
  • October 20, 2025
  • February 20, 2026
  • June 22, 2026
  • October 19, 2026
The following full proposal deadlines apply to Renewal/Resubmission/Revision grant applications (due by 5:00 pm local time of applicant organization): 

  • March 21, 2024
  • July 19, 2024
  • November 21, 2024
  • March 21, 2025
  • July 23 , 2025
  • November 20, 2025
  • March 20, 2026
  • July 22, 2026
  • November 19, 2026
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Your history with this funder
No saved opportunities from this funder yet
Save this opportunity to add notes...
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Forecasted Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih) help icon

Don't miss out on other good fit funders!

Get personalized grant recommendations, tracking and more by creating a free 14-day account.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed August 24, 2023 and last updated August 24, 2023